Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: Influence on patient selection for surgery

Archives of Surgery

Volumn 146, Issue 7, 2011, Pages 836-843

  Donahue, Timothy R ^a   Isacoff, William H ^a   Hines, O Joe ^a   Tomlinson, James S ^a,b   Farrell, James J ^a,b   Bhat, Yasser M ^a   Garon, Edward ^a   Clerkin, Barbara ^a   Reber, Howard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Greater Los Angeles Veterans Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; INOPERABLE CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TUMOR VOLUME; VASCULAR TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR NEOPLASMS;

EID: 79960391111     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.152     Document Type: Article

References (28)

1. American Cancer Society. Cancer facts and figures 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf. Accessed April 25, 2011.
2. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463-475. (Pubitemid 26337555)
3. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008;143(12):1166- 1171.
4. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326(7):455-465.
5. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg. 2008;12(9):1600-1608.
6. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997;174(6):605-609. (Pubitemid 28008688)
7. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25(18):2607-2615. (Pubitemid 47041235)
8. Amano H, Miura F, Toyota N, et al. Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer? J Hepatobiliary Pancreat Surg. 2009;16(6):850-857.
9. Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247(2):300-309. (Pubitemid 351156774)
10. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935-950. (Pubitemid 39600636)
11. Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol. 2009;16(4):817-825.
12. Compton CC, Henson DE. Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: a basis for checklists: Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1997;121(11):1129-1136.
13. Coley SC, Strickland NH, Walker JD, Williamson RC. Spiral CT and the preoperative assessment of pancreatic adenocarcinoma. Clin Radiol. 1997;52(1):24-30.
14. Li H, Zeng MS, Zhou KR, Jin DY, Lou WH. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr. 2005;29(2):170-175. (Pubitemid 40411299)
15. O'Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol. 1999;173(6):1513-1518.
16. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreaticphase, thin-section helical CT. AJR Am J Roentgenol. 1997;168(6):1439-1443. (Pubitemid 27232661)
17. Vedantham S, Lu DS, Reber HA, Kadell B. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. AJR Am J Roentgenol. 1998;170(2):377-383. (Pubitemid 28083842)
18. Smith SL, Rajan PS. Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol. 2004;59(1):26-38. (Pubitemid 38054730)
19. Klauss M, Mohr A, von Tengg-Kobligk H, et al. A new invasion score for determining the resectability of pancreatic carcinomas with contrast-enhanced multidetector computed tomography. Pancreatology. 2008;8(2):204-210. (Pubitemid 351670371)
20. Zamboni GA, Kruskal JB, Vollmer CM, Baptista J, Callery MP, Raptopoulos VD. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology. 2007;245(3):770-778. (Pubitemid 350127347)
21. Lopez Hänninen E, Amthauer H, Hosten N, et al. Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology. 2002;224(1):34-41. (Pubitemid 34680372)
22. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833-848.
23. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751-1756.
24. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501-5503. (Pubitemid 17152971)
25. DiMagno EP, Reber HA, Tempero MA; American Gastroenterological Association. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117(6):1464-1484.
26. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94(7):1941-1946.
27. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918-5922.
28. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15(12):3512-3520.